Fibrobiologics Inc (FBLG)

$1.40 +0.03 (2.52%)
Market Cap 4.74M
Revenue (ttm) 0.00
Net Income (ttm) -18.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 72,706
Avg Vol 378,049
Day's Range N/A - N/A
Shares Out 3.51M
Stochastic %K 31%
Beta 1.07
Analysts Strong Sell
Price Target $80.00

Company Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It al...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 671 5150
Address:
455 East Medical Center Boulevard, Suite 300, Houston, United States
FeliciaMath
FeliciaMath Apr. 12 at 2:58 PM
some current bags/still holding: $GCTK, $SEGG, $FBLG, $OWLT, $ALMU
0 · Reply
focafoca99
focafoca99 Apr. 10 at 6:08 PM
$FBLG presented preclinical data on a thymus organoid platform designed to restore thymic function and counter age-related immune decline.
0 · Reply
DekmarTrades
DekmarTrades Apr. 10 at 1:14 PM
THE BEST NEWS of Pre Market! These stocks are gapping from credible catalyst this morning! $RAYA $LNKS $EOSE $CIGL $FBLG
0 · Reply
focafoca99
focafoca99 Apr. 10 at 12:19 AM
$FBLG entered a lease termination deal to buy out a sublease, making this more of a real-estate cleanup item than an operating catalyst.
0 · Reply
MaxHardcore
MaxHardcore Apr. 9 at 8:23 PM
$FBLG Form 8-K FibroBiologics, Inc. For: Apr 03 10K WIZARD 4:15 PM ET 4/09/2026 A A A http://archive.fast-edgar.com/20260409/A52B222DZZ2R5TZZ2R9B2ZYORTIHZZ22Z282 Filed on: April 9, 2026
0 · Reply
11__11
11__11 Apr. 8 at 7:26 AM
$FBLG Watch
0 · Reply
FeliciaMath
FeliciaMath Apr. 6 at 3:39 PM
bought $FBLG at 1.51
1 · Reply
11__11
11__11 Apr. 6 at 3:01 PM
$FBLG
0 · Reply
Goldwave9
Goldwave9 Apr. 5 at 7:00 AM
$FBLG All the ingredients but...don't look at that 8k
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:26 PM
$FBLG closed its $3.0 million public offering of shares or equivalents plus warrants.
0 · Reply
Latest News on FBLG
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

Apr 10, 2026, 8:30 AM EDT - 4 days ago

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

FibroBiologics Announces Closing of $3 Million Public Offering

Apr 2, 2026, 4:01 PM EDT - 11 days ago

FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics Announces Pricing of $3 Million Public Offering

Mar 31, 2026, 8:00 PM EDT - 13 days ago

FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

Mar 31, 2026, 4:15 PM EDT - 13 days ago

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

Mar 25, 2026, 4:30 PM EDT - 19 days ago

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

Mar 12, 2026, 8:30 AM EDT - 4 weeks ago

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Mar 5, 2026, 8:30 AM EST - 5 weeks ago

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Mar 2, 2026, 8:30 AM EST - 6 weeks ago

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

FibroBiologics to Present at the BIO Investment & Growth Summit

Feb 26, 2026, 8:30 AM EST - 6 weeks ago

FibroBiologics to Present at the BIO Investment & Growth Summit

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 4:30 PM EST - 6 weeks ago

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

Feb 23, 2026, 8:30 AM EST - 7 weeks ago

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

Feb 10, 2026, 8:30 AM EST - 2 months ago

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Feb 5, 2026, 8:30 AM EST - 2 months ago

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

FibroBiologics to Present at the DealFlow Discovery Conference

Jan 20, 2026, 8:30 AM EST - 3 months ago

FibroBiologics to Present at the DealFlow Discovery Conference

FibroBiologics CEO Issues Letter to Shareholders

Jan 7, 2026, 8:30 AM EST - 3 months ago

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Jan 6, 2026, 8:30 AM EST - 3 months ago

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

Jan 5, 2026, 8:30 AM EST - 3 months ago

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Dec 31, 2025, 8:30 AM EST - 3 months ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:05 PM EST - 4 months ago

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 4 months ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

Dec 10, 2025, 11:36 AM EST - 4 months ago

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Dec 10, 2025, 8:30 AM EST - 4 months ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

FibroBiologics Announces Payoff of Outstanding Debt

Nov 26, 2025, 8:30 AM EST - 4 months ago

FibroBiologics Announces Payoff of Outstanding Debt

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 4:05 PM EST - 4 months ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 5 months ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 20, 2025, 8:00 AM EST - 5 months ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 7:03 PM EST - 5 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 5 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:30 PM EDT - 5 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics to Present at Bio-Europe 2025

Oct 24, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics to Present at the 2025 ThinkEquity Conference

Oct 14, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 23, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 12, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 11, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Sep 10, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:30 PM EDT - 9 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 28, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 11, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 9, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jul 7, 2025, 4:35 PM EDT - 10 months ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Jun 16, 2025, 4:35 PM EDT - 10 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

FibroBiologics to Present at the BIO International Convention 2025

Jun 16, 2025, 9:50 AM EDT - 10 months ago

FibroBiologics to Present at the BIO International Convention 2025

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

Jun 9, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

May 16, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:30 PM EDT - 11 months ago

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Presenting at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 1 year ago

FibroBiologics Presenting at the ThymUS 2025 Meeting

FibroBiologics Presents at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 1 year ago

FibroBiologics Presents at the ThymUS 2025 Meeting

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Apr 11, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

Apr 8, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

FeliciaMath
FeliciaMath Apr. 12 at 2:58 PM
some current bags/still holding: $GCTK, $SEGG, $FBLG, $OWLT, $ALMU
0 · Reply
focafoca99
focafoca99 Apr. 10 at 6:08 PM
$FBLG presented preclinical data on a thymus organoid platform designed to restore thymic function and counter age-related immune decline.
0 · Reply
DekmarTrades
DekmarTrades Apr. 10 at 1:14 PM
THE BEST NEWS of Pre Market! These stocks are gapping from credible catalyst this morning! $RAYA $LNKS $EOSE $CIGL $FBLG
0 · Reply
focafoca99
focafoca99 Apr. 10 at 12:19 AM
$FBLG entered a lease termination deal to buy out a sublease, making this more of a real-estate cleanup item than an operating catalyst.
0 · Reply
MaxHardcore
MaxHardcore Apr. 9 at 8:23 PM
$FBLG Form 8-K FibroBiologics, Inc. For: Apr 03 10K WIZARD 4:15 PM ET 4/09/2026 A A A http://archive.fast-edgar.com/20260409/A52B222DZZ2R5TZZ2R9B2ZYORTIHZZ22Z282 Filed on: April 9, 2026
0 · Reply
11__11
11__11 Apr. 8 at 7:26 AM
$FBLG Watch
0 · Reply
FeliciaMath
FeliciaMath Apr. 6 at 3:39 PM
bought $FBLG at 1.51
1 · Reply
11__11
11__11 Apr. 6 at 3:01 PM
$FBLG
0 · Reply
Goldwave9
Goldwave9 Apr. 5 at 7:00 AM
$FBLG All the ingredients but...don't look at that 8k
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:26 PM
$FBLG closed its $3.0 million public offering of shares or equivalents plus warrants.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 10:33 PM
$FBLG RSI: 6.14, MACD: -1.1868 Vol: 2.16, MA20: 5.06, MA50: 5.65 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Apr. 2 at 5:31 PM
$FBLG All the crying yesterday is gone 🤷
0 · Reply
MisoHawny
MisoHawny Apr. 2 at 2:51 PM
$FBLG then 3.1, 3.9, 4.8, 5.2, 5.9. If it continues, which is f’d at this point
0 · Reply
MisoHawny
MisoHawny Apr. 2 at 2:47 PM
$FBLG if it holds 1.6 we will see 1.84 and then 2.2. 
0 · Reply
MisoHawny
MisoHawny Apr. 2 at 2:46 PM
$FBLG we will see 1.6
1 · Reply
MaxHardcore
MaxHardcore Apr. 1 at 8:25 PM
$FBLG Form 424B4 FibroBiologics, Inc. 10K WIZARD 4:19 PM ET 4/01/2026 A A A http://archive.fast-edgar.com/20260401/AJ2ZBQ2DZW2RRZZZ272N2ZYNFUHKZZ22ZS82 Filed on: April 1, 2026
0 · Reply
thegoodcall
thegoodcall Apr. 1 at 7:56 PM
$FBLG AH could be huge run
0 · Reply
thegoodcall
thegoodcall Apr. 1 at 5:50 PM
$FBLG that stock will run like a horse AH. It can do over %125
0 · Reply
BullBobo
BullBobo Apr. 1 at 4:44 PM
$FBLG Next resistance $1.06
0 · Reply
CranialRocK
CranialRocK Apr. 1 at 4:36 PM
$FBLG POS!
0 · Reply
CranialRocK
CranialRocK Apr. 1 at 4:24 PM
$FBLG WEll it WASSS a good day! WTF??
0 · Reply
prettyboystocks
prettyboystocks Apr. 1 at 4:10 PM
$FBLG r u fucking serious? WTF was that? So not cool
0 · Reply